Scientific literature describes that sumatriptan is metabolized by oxidative deamination of its dimethylaminoethyl residue by monoamine oxidase A (MAO A) and not by cytochrome P450 (CYP)-mediated demethylation, as is usual for such structural elements. Using recombinant human enzymes and HPLC-MS analysis, we found that CYP enzymes may also be involved in the metabolism of sumatriptan. The CYP1A2, CYP2C19, and CYP2D6 isoforms converted this drug into N-desmethyl sumatriptan, which was further demethylated to N,N-didesmethyl sumatriptan by CYP1A2 and CYP2D6. Otherwise, sumatriptan and its two desmethyl metabolites were metabolized by recombinant MAO A but not by MAO B to the corresponding acetaldehyde, with sumatriptan being only a poor substrate for MAO A compared to the N-demethylated and the N,N-didemethylated derivatives.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849828 | PMC |
| http://dx.doi.org/10.1002/prp2.1051 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First report on QSAR modelling for chemical penetration enhancement ratio (ER) of different FDA-approved drugs in Poloxamer 407: A next step towards better skin permeability of drugs.
Int J Pharm
January 2025
Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India. Electronic address:
Poloxamer 407 is a versatile excipient that enhances drug solubilization and prolongs drug release. Poloxamers are non-ionic tri-block copolymers composed of a central hydrophobic chain of polyoxypropylene flanked by two hydrophilic chains of polyoxyethylene. Various researchers have utilized Poloxamer 407 in topical and transdermal drug delivery systems, and it has also been reported to enhance skin permeability.
View Article and Find Full Text PDFMeningeal K ATP channels contribute to behavioral responses in preclinical migraine models.
Pain
February 2025
Department of Neuroscience, The Center for Advanced Pain Studies, The University of Texas at Dallas, Richardson, TX, United States.
Human experimental studies have shown that levcromakalim, an ATP-sensitive potassium (K ATP ) channel opener, induces migraine attacks in people with migraine but not in healthy volunteers. However, the exact site of action for K ATP channels in migraine pathophysiology remains unclear. This study investigates the role of these channels in the meninges in eliciting behavioral hypersensitivity responses in mice.
View Article and Find Full Text PDFThe neurotrophic factor artemin and its receptor GFRα3 mediate migraine-like pain via the ion channel TRPM8.
Cephalalgia
November 2024
Neurobiology Section, Department of Biological Sciences, University of Southern California, Los Angeles, CA, USA.
Article Synopsis
- Genetic Basis of Migraine
- : Migraine is largely polygenic, with many genetic variants identified through genome-wide association studies. Key mutations are linked to the TRPM8 channel, which senses cold but may have different activation mechanisms related to migraine.
- Role of Artemin and GFRα3
- : The study explores how the neurotrophic factor artemin and its receptor GFRα3 influence migraine-related pain through their effects on TRPM8, potentially affecting cold sensitivity and pain responses in migraine models.
- Preclinical Findings
- : Experiments on mice show that GFRα3 is crucial for mechanical sensitivity in migraine, as blocking artemin reduces migraine-like symptoms, highlighting its significance in
Regulatory T cells require peripheral CCL2-CCR2 signaling to facilitate the resolution of medication overuse headache-related behavioral sensitization.
J Headache Pain
November 2024
Department of Anesthesiology, Washington University in St. Louis School of Medicine, St. Louis, MO, 63110, USA.
Article Synopsis
- Medication overuse headache (MOH) occurs from excessive use of headache medication, like sumatriptan, and is linked to changes in the CCL2-CCR2 and CGRP signaling pathways, which may contribute to chronic migraine symptoms.
- The study involved administering sumatriptan to mice for 12 days to observe changes in sensitivity and to evaluate how specific signaling pathways were affected, using both genetic techniques and treatments.
- Results indicated that inhibiting CCL2 and CCR2 signaling did not prevent sumatriptan-induced sensitization, and LD-IL-2 treatment was effective in helping to resolve the sensitization caused by overuse of the medication.
Population pharmacokinetic modeling of zavegepant, a calcitonin gene-related peptide receptor antagonist, in healthy adults and patients with migraine.
CPT Pharmacometrics Syst Pharmacol
January 2025
Pfizer Inc., Groton, Connecticut, USA.
Article Synopsis
- Zavegepant (ZAVZPRET™) is a selective medication for treating acute migraines in adults, targeting specific receptors related to migraine pathways.
- A comprehensive analysis of its pharmacokinetics determined how zavegepant is absorbed, distributed, and eliminated from the body, utilizing data from multiple clinical trials.
- The findings revealed that zavegepant has low bioavailability rates when taken intranasally (5.1%) or orally (0.65%), with factors like age and sex not significantly affecting its pharmacokinetics, but certain conditions (like moderate liver impairment) could impact its clearance.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!